华大基因 reported revenue of ¥1.79B for the period ended 2026-06-30, +9.6% year on year. Net income was ¥0.05B, a 2.7% net margin on a 41.5% gross margin. The largest revenue line is 精准医学检测综合解决方案 at 51% of the total. Free cash flow for the period was ¥-0.16B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.79B | +9.6% |
| Gross profit | ¥0.74B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | +1048.6% |
| Gross margin | 41.5% | Net margin 2.7% |
| Revenue Q/Q | +21.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 精准医学检测综合解决方案 | ¥0.92B | 51.3% |
| 生育健康基础研究和临床应用服务 | ¥0.35B | 19.4% |
| 多组学大数据服务与合成业务 | ¥0.34B | 18.8% |
| 肿瘤与慢病防控及转化医学类服务 | ¥0.14B | 7.6% |
| 感染防控基础研究和临床应用服务 | ¥0.04B | 2.4% |
| 其他(补充) | ¥0.01B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.05B | 58.5% |
| R&D | ¥0.17B | 9.4% |
| SG&A | ¥0.46B | 25.7% |
| Tax & other | ¥0.01B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥11.22B |
| Total liabilities | ¥2.59B |
| Shareholders' equity | ¥8.63B |
| Equity / assets | 76.9% |
| Operating cash flow | ¥-0.10B |
| Capital expenditure | ¥0.06B |
| Free cash flow | ¥-0.16B |
| Cash conversion (OCF / net income) | -579% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力 ・ 赛意信息 ・ 创业黑马
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies